This CPB has been revised to state that the following are considered experimental and investigational: (i) ketamine (intranasal, intravenous, oral, or subcutaneous) for generalized anxiety and social anxiety disorders, and substance use disorders; and (ii) intravenous or oral ketamine for burn wound care.

The title of this CPB has been changed to “Ketamine for the Treatment of Depression and Other Psychiatric Disorders”.